Navigation

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib [ID498]

Vemurafenib for the treatment of unresectable locally advanced or metastatic BRAF V600 mutation positive malignant melanoma

Status: History
Expected date of issue: December 2012
Referral date: September 2011
Process: STA
Notes:

Scoped within Batch 19

Topic area:
 

NICE project team

Executive Lead: TBC
Technical Lead: Kumar Perampaladas
Communications manager: Alice Law
Project manager: Bijal Joshi
Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: 01/02/12
1st appraisal committee meeting: 14 May 2012
2nd appraisal committee meeting 18 July 2012
3rd appraisal committee meeting: 18 September 2012
Top


 

Consultees and commentators

To be confirmed

Top


 

Key documents

This page was last updated: 12 December 2012

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.